Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wally Smith

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Drug and Alcohol Dependence|March 17, 2022
Gender-specific correlates of nonmedical use of prescription medications in a diverse primary care sampleTaylor B Crouch, Caitlin E Martin, Kathryn Polak, et al.
Pain Medicine (Malden, Mass.)|October 11, 2025
Relationships Among Childhood Trauma, Central Sensitization, and Opioid-Related Risks in a Community Sample of Adults with Chronic Pain on OpioidsTaylor B Crouch, John A Sturgeon, Maggie Nguyen, et al.
Modern Clinical Medicine Research|September 16, 2021
Survey of Physician Perspective towards Management of Pain for Chronic Conditions in the Emergency DepartmentDaniel Sop, Wally Smith, Abdulkhaliq Alsalman, et al.
Biomed Research International|February 7, 2023
Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview StudyClark Brown, Modupe Idowu, Richard Drachtman, et al.
American Journal of Hematology|June 1, 2010
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-upMartin H Steinberg, William F McCarthy, Oswaldo Castro, et al.
American Journal of Hematology|March 29, 2014
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell diseaseMarvin E Reid, Amal El Beshlawy, Adlette Inati, et al.
Blood Advances|August 26, 2025
Improvements in Health-Related Quality of Life in Patients with Severe Sickle Cell Disease After Exagamglogene AutotemcelAkshay Sharma, Franco Locatelli, Monica Bhatia, et al.
American Journal of Hematology|January 15, 2019
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot studyLakshmanan Krishnamurti, Donna S Neuberg, Keith M Sullivan, et al.
Blood Advances|August 27, 2025
Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene AutotemcelJosu de la Fuente, Haydar Frangoul, Peter Lang, et al.
JAMA|April 4, 2003
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatmentMartin H Steinberg, Franca Barton, Oswaldo Castro, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Drug and Alcohol Dependence|March 17, 2022
Gender-specific correlates of nonmedical use of prescription medications in a diverse primary care sampleTaylor B Crouch, Caitlin E Martin, Kathryn Polak, et al.
Pain Medicine (Malden, Mass.)|October 11, 2025
Relationships Among Childhood Trauma, Central Sensitization, and Opioid-Related Risks in a Community Sample of Adults with Chronic Pain on OpioidsTaylor B Crouch, John A Sturgeon, Maggie Nguyen, et al.
Modern Clinical Medicine Research|September 16, 2021
Survey of Physician Perspective towards Management of Pain for Chronic Conditions in the Emergency DepartmentDaniel Sop, Wally Smith, Abdulkhaliq Alsalman, et al.
Biomed Research International|February 7, 2023
Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview StudyClark Brown, Modupe Idowu, Richard Drachtman, et al.
American Journal of Hematology|June 1, 2010
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-upMartin H Steinberg, William F McCarthy, Oswaldo Castro, et al.
American Journal of Hematology|March 29, 2014
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell diseaseMarvin E Reid, Amal El Beshlawy, Adlette Inati, et al.
Blood Advances|August 26, 2025
Improvements in Health-Related Quality of Life in Patients with Severe Sickle Cell Disease After Exagamglogene AutotemcelAkshay Sharma, Franco Locatelli, Monica Bhatia, et al.
American Journal of Hematology|January 15, 2019
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot studyLakshmanan Krishnamurti, Donna S Neuberg, Keith M Sullivan, et al.
Blood Advances|August 27, 2025
Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene AutotemcelJosu de la Fuente, Haydar Frangoul, Peter Lang, et al.
JAMA|April 4, 2003
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatmentMartin H Steinberg, Franca Barton, Oswaldo Castro, et al.
Pageof 4